microorganisms

IMPACT FACTOR 4.2

Indexed in: PubMed

CITESCORE 7.7

an Open Access Journal by MDPI

Advances and Challenges in Mycobacterium tuberculosis Research and Therapeutics Development

Guest Editors:

Dr. Louis Grandjean
Great Ormond Street Hospital London WC1N 3JH, UK; Imperial College London, London SW7 2BU, UK

Dr. Marc Woodman
Guys and St Thomas' NHS Trust, London SE1 9RS, UK

Dr. Shruthi Chandran
Department of Microbiology and Infectious diseases, Royal London Hospital, Barts NHS Health trust, London E1 1FR, UK

Deadline for manuscript submissions:
closed (31 December 2021)

Message from the Guest Editors

Tuberculosis (TB) is the leading cause of death worldwide from a single infectious agent and is one of the top ten causes of death overall, causing an estimated 10 million infections and 1.4 million deaths in 2019.

In recent years, molecular techniques such as GeneXpert and Whole Genome Sequencing have led to improvements in diagnostic efficiency, contact tracing, and resistance testing and contributed to our understanding of key aspects of the organism, such as transmission and virulence. Furthermore, novel therapeutic agents provide more options for treatment of Multi-Drug Resistant Tuberculosis (MDR-TB), and injectable free regimens may in future improve compliance and cure rates.

At a time when progress in the fight against TB is being threatened by the global COVID-19 pandemic, it is important to focus on bold technological improvements such as improved vaccines, point-of-care diagnostic testing, treatment for latent TB, and shorter treatment regimens for active TB. For this Special Issue, we invite contributions on all aspects of the development of tuberculosis diagnostics and therapeutics.

microorganisms

IMPACT FACTOR 4.2 | Indexed in: PubMed | CITESCORE 7.7

an Open Access Journal by MDPI

Editor-in-Chief

Dr. Nico Jehmlich
Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.
Journal Rank: JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Contact Us

Microorganisms Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/microorganisms
microorganisms@mdpi.com
𝕏@Micro_MDPI